📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
79 announcements match the current filters (relevance ≥ 5).
Aurobindo Pharma Unit-VII Receives US FDA Form 483 with 9 Procedural Observations
The US FDA concluded an inspection of Aurobindo Pharma's Unit-VII, an oral solid dosage manufacturing facility in Telangana, on February 10, 2026. The inspection, which began on January 28, resulted in the issuance of a Form 483 with 9 observations. Management has characterized these observations as procedural in nature and stated there is no immediate impact on financial or operational activities. The company is preparing a formal response to be submitted within the stipulated regulatory timelines.
Key Highlights
US FDA inspection conducted at Unit-VII oral solid dosage facility from January 28 to February 10, 2026.
Form 483 issued by the regulator containing a total of 9 observations.
Company management confirms all 9 observations are procedural in nature.
No immediate quantifiable financial or operational impact reported by the company.
Unit-VII is located at the Special Economic Zone (Pharma) in Jedcherla, Telangana.
👀 What to Watch
Investors should monitor the final classification of the inspection by the US FDA, as 9 observations is a significant count even if procedural. Watch for updates on whether the facility receives Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) status.
Aurobindo Pharma Q3FY26: Revenue up 8.4% to ₹8,646 Cr, EBITDA Margins steady at 20.5%
Aurobindo Pharma reported a steady Q3FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 crore, primarily driven by a robust 27.4% surge in the European market. EBITDA rose 9% YoY to ₹1,773 crore with margins remaining stable at 20.5%, supported by operational efficiencies and stable gross margins. While US revenues remained stable at $420 million, the company generated strong free cash flows of $118 million during the quarter. The company maintains a healthy net cash position of $251 million even after accounting for the Khandelwal Labs acquisition.
Key Highlights
Consolidated revenue grew 8.4% YoY to ₹8,646 crore, led by a 27.4% growth in Europe formulations to ₹2,703 crore.
Net Profit increased by 7.6% YoY to ₹910 crore, while EBITDA margins improved slightly to 20.5%.
US business remained stable with 9 product launches and 7 approvals, contributing 43.2% of total revenue.
R&D investment stood at ₹409 crore (4.7% of sales), focusing on biosimilars and specialty products.
Net cash position reached $251 million as of December 2025, after appropriating cash for the Khandelwal Labs acquisition.
👀 What to Watch
Investors should focus on the company's successful diversification into European markets and its strong cash generation. Monitor the progress of the biosimilar pipeline (CuraTeQ) as the filing for Denosumab has seen a slight delay to mid-2026.
Aurobindo Pharma to Acquire 26% Stake in Garuda Renewables for ₹66 Crores
Aurobindo Pharma has approved an investment of ₹66 crores to acquire a 26% stake in Garuda Renewables Private Limited, a special purpose vehicle for hybrid wind and solar power. This strategic move includes a Power Purchase Agreement to procure renewable energy for the company's operations. The investment is designed to achieve substantial long-term savings in power costs while significantly improving the company's ESG profile through reduced carbon emissions. The transaction is expected to be completed within six months, subject to regulatory approvals.
Key Highlights
Investment of ₹66 crores to acquire up to 26% equity stake in Garuda Renewables Private Limited.
Strategic shift to hybrid wind and solar energy procurement via a long-term Power Purchase Agreement.
Target entity is a subsidiary of Ecoren Energy, which has a 5GW commissioned/under-construction track record.
Expected completion timeline of 6 months for the acquisition process.
Aims to reduce operational power costs and enhance the company's green energy commitment.
👀 What to Watch
Investors should view this as a positive step toward operational efficiency and ESG compliance. While the immediate financial impact is small relative to Aurobindo's size, the long-term power cost savings will support margin stability.
Aurobindo Pharma Appoints Dr. Punita Kumar-Sinha as Independent Director for 3-Year Term
Aurobindo Pharma has appointed Dr. (Mrs.) Punita Kumar-Sinha as an Additional Non-Executive Independent Director for a three-year term effective February 9, 2026. Dr. Kumar-Sinha is a seasoned global investor and former Senior Managing Director at Blackstone Asia Advisors, bringing over 30 years of capital markets experience. Simultaneously, Dr. (Mrs.) Deepali Pant Joshi will step down from the board on February 10, 2026, following the completion of her two-year tenure. This board refresh adds significant expertise in governance, ESG, and investment management to the company.
Key Highlights
Dr. (Mrs.) Punita Kumar-Sinha appointed as Independent Director for a 3-year term ending February 8, 2029.
The new appointee is a former Senior Managing Director and CIO at Blackstone Asia Advisors with a PhD from Wharton.
Dr. (Mrs.) Deepali Pant Joshi ceases to be a Director effective February 10, 2026, after completing a 2-year term.
Dr. Kumar-Sinha holds a Chemical Engineering degree from IIT Delhi and is a CFA charterholder.
The appointment is subject to the approval of the company's members.
👀 What to Watch
Investors should view this as a positive development for corporate governance, as the new director brings high-caliber global investment and ESG expertise. No immediate action is required, but the move strengthens the board's oversight capabilities.
Aurobindo Pharma Q3 FY26 Net Profit Rises 7.6% to ₹910 Cr; Europe Revenue Surges 27%
Aurobindo Pharma reported a steady Q3 FY26 with consolidated revenue growing 8.4% YoY to ₹8,646 Cr, primarily driven by a robust 27.4% growth in the European market. Net profit increased by 7.6% YoY to ₹910 Cr, despite a one-time impact of ₹65 Cr related to new labor code costs. The US business saw modest growth of 2.2%, while the API segment faced a slight decline of 4.3% YoY. The company maintains a strong financial position with a net cash surplus of $251 million and generated free cash flows of $118 million during the quarter.
Key Highlights
Revenue from operations grew 8.4% YoY to ₹8,646 Cr, led by Europe and ARV segments.
Europe formulations revenue jumped 27.4% YoY to ₹2,703 Cr, now contributing 31.3% of total revenue.
EBITDA margin (before Forex and Other Income) remained stable at 20.5% compared to 20.4% in the previous year.
Net profit reached ₹910 Cr, including a one-time ₹65 Cr provision for labor code changes.
Strong balance sheet with $251 million net cash and 7 new USFDA ANDA approvals received during the quarter.
👀 What to Watch
Investors should note the strong momentum in the European market which is successfully offsetting slower growth in the US and API segments. The healthy cash position and consistent R&D investment support long-term growth prospects.
Aurobindo Pharma Q3FY26 Net Profit Rises 7.6% to ₹910 Cr; Revenue Up 8.4% at ₹8,646 Cr
Aurobindo Pharma reported a steady Q3FY26 performance with consolidated revenue growing 8.4% YoY to ₹8,646 crore, primarily driven by a robust 27.4% growth in the Europe segment. EBITDA margins remained healthy at 20.5%, supported by stable gross margins and operational efficiencies. The company maintained a strong net cash position of $251 million even after accounting for the Khandelwal Labs acquisition. While the US market saw modest 2.2% growth, the biosimilar pipeline under CuraTeQ is progressing with key filings planned for 2026.
Key Highlights
Consolidated Revenue increased 8.4% YoY to ₹8,646 crore, with Europe business growing 27.4% to ₹2,703 crore.
EBITDA grew 9.0% YoY to ₹1,773 crore with a margin of 20.5%, up 11 bps from the previous year.
Net Profit attributable to owners rose 7.6% YoY to ₹910 crore, resulting in an EPS of ₹15.67.
Strong balance sheet with a net cash position of US$ 251 million and free cash flow generation of $118 million in Q3.
R&D investment stood at ₹409 crore (4.7% of sales), focusing on biosimilars and specialty products.
👀 What to Watch
Investors should monitor the company's successful diversification into the European market and the upcoming regulatory filings for its biosimilar pipeline in 2026. The strong cash position and stable margins make it a solid pick in the large-cap pharma space.
Aurobindo Pharma Q3 Consolidated PAT Rises 7.6% YoY to ₹9,098 Million
Aurobindo Pharma reported a steady performance for Q3 FY26, with consolidated revenue from operations growing 8.4% YoY to ₹86,459 million. Net profit for the quarter stood at ₹9,098 million, up from ₹8,455.7 million in the same period last year, despite an exceptional charge of ₹653.3 million related to new labor code provisions. The company's performance was bolstered by a significant 21.7% reduction in finance costs compared to the previous year. For the nine-month period, the company has maintained a stable profit level of ₹25,821.3 million.
Key Highlights
Consolidated Revenue from operations increased by 8.4% YoY to ₹86,459 million.
Consolidated Profit After Tax (PAT) grew by 7.6% YoY to ₹9,098 million.
Finance costs decreased significantly by 21.7% YoY to ₹927.7 million from ₹1,184.8 million.
An exceptional item of ₹653.3 million was recorded due to the implementation of new Labour Codes affecting employee benefits.
Basic EPS improved to ₹15.67 for the quarter compared to ₹14.56 in the previous year's corresponding quarter.
👀 What to Watch
Investors should take note of the steady revenue growth and the significant reduction in interest expenses which indicates better debt management. The stock remains a key pharmaceutical play, though the non-recurring impact of labor code adjustments should be factored into margin expectations.
Aurobindo Pharma Q3 FY26 Revenue Up 8.4% YoY to ₹8,646 Cr; Invests ₹66 Cr in Renewable Energy
Aurobindo Pharma reported a consolidated revenue of ₹8,645.9 crore for Q3 FY26, an 8.4% increase compared to ₹7,978.5 crore in the same quarter last year. Standalone Profit After Tax (PAT) showed strong growth, rising to ₹582.1 crore from ₹472.1 crore YoY. The company is strategically investing ₹66 crore for a 26% stake in Garuda Renewables to secure hybrid wind and solar power. Furthermore, the board approved the merger of its vaccine and biologics subsidiaries to streamline its specialized portfolio.
Key Highlights
Consolidated revenue from operations grew 8.4% YoY to ₹86,459 million in Q3 FY26.
Standalone Profit After Tax (PAT) increased 23.3% YoY to ₹5,820.7 million.
Approved ₹66 crore investment for a 26% stake in Garuda Renewables Private Limited for hybrid energy procurement.
Board approved the merger of Auro Vaccines Private Limited into Curateq Biologics Private Limited to consolidate operations.
Recognized a non-recurring exceptional item of ₹173.8 million related to the enactment of new Labour Codes.
👀 What to Watch
Investors should view the steady revenue growth and the strategic shift toward renewable energy for cost optimization as positive signs. The consolidation of biologics and vaccine arms suggests a focused approach to high-growth segments, warranting a 'Hold' or 'Accumulate' stance.
Aurobindo Pharma's Eugia Unit III Receives 11 US FDA Observations
Aurobindo Pharma's wholly owned subsidiary, Eugia Pharma Specialities Ltd., completed a US FDA inspection at its Unit III formulation facility in Telangana. The inspection, which took place from January 27 to February 06, 2026, concluded with 11 observations. The company has characterized these observations as procedural in nature and plans to respond within the stipulated timeframe. While the company reports no immediate financial impact, the double-digit count of observations requires careful monitoring for potential regulatory escalation.
Key Highlights
US FDA inspection conducted at Eugia Pharma's Unit III facility from January 27 to February 06, 2026
The inspection concluded with a total of 11 observations issued by the regulator
Management has classified the observations as procedural rather than systemic or data integrity issues
The company stated there is no immediate impact on current financial or operational activities
A formal response to the observations will be submitted to the US FDA within the required timeline
👀 What to Watch
Investors should monitor the final classification of the inspection by the US FDA, as 11 observations is a relatively high number that could delay new product approvals if not resolved quickly. Maintain a watch on whether the facility receives a Voluntary Action Indicated (VAI) or Official Action Indicated (OAI) status.
Aurobindo Pharma Clarifies Volume Surge Linked to Govt's Minimum Import Price on Penicillin-G
Aurobindo Pharma has clarified that the recent significant movement in its share volume is likely due to a Government of India notification dated January 29, 2026. The government imposed a Minimum Import Price (MIP) on Penicillin-G, 6-APA, and Amoxicillin Trihydrate to protect domestic manufacturers. The company's wholly-owned subsidiary, Lyfius Pharma, is a major manufacturer of these products and stands to benefit from this policy. The company confirmed that all material information is already in the public domain and no other undisclosed developments exist.
Key Highlights
Government notified Minimum Import Price (MIP) on Penicillin-G and derivatives on Jan 29, 2026
Wholly-owned subsidiary Lyfius Pharma manufactures Penicillin-G and downstream derivatives
MIP is expected to reduce competition from cheap imports for the company's domestic production
Company confirms no other undisclosed material events are influencing the share price or volume
The clarification was issued in response to queries from NSE and BSE regarding trading volume
👀 What to Watch
Investors should view the government's MIP notification as a positive tailwind for Aurobindo's API business and its subsidiary Lyfius Pharma. Monitor the company's upcoming quarterly results for signs of improved margins in the domestic antibiotics segment.
Aurobindo Pharma Clarifies Volume Surge; Cites New Govt Minimum Import Price on Penicillin-G
Aurobindo Pharma clarified that the recent spike in trading volume is likely due to the Government of India's January 29, 2026, notification imposing a Minimum Import Price (MIP) on Penicillin-G, 6-APA, and Amoxicillin Trihydrate. The company's wholly-owned subsidiary, Lyfius Pharma, is a direct manufacturer of these products and stands to benefit from protection against low-cost imports. Management stated that this information was already in the public domain via the DGFT website and no undisclosed material events exist. The move is seen as a structural positive for the company's domestic antibiotic intermediate production.
Key Highlights
Government notified Minimum Import Price (MIP) on Jan 29, 2026, for Penicillin-G and derivatives.
Wholly-owned subsidiary Lyfius Pharma manufactures Penicillin-G, 6-APA, and Amoxicillin Trihydrate.
Company attributes significant share volume movement to market reaction to this public DGFT notification.
Management confirms no other undisclosed material information or pending announcements exist.
MIP applies to imports intended for domestic consumption, favoring domestic manufacturers like Lyfius.
👀 What to Watch
Investors should monitor the capacity utilization and margin improvement at Lyfius Pharma following the MIP implementation. This regulatory protection reduces import competition and strengthens Aurobindo's backward integration strategy.
Aurobindo Pharma Clarifies Volume Spurt; Cites Govt MIP on Penicillin-G and Derivatives
Aurobindo Pharma responded to stock exchange queries regarding a significant increase in trading volume observed recently. The company attributed this market interest to the Government of India's notification on January 29, 2026, which imposed a Minimum Import Price (MIP) on Penicillin-G, 6-APA, and Amoxicillin Trihydrate. Its wholly-owned subsidiary, Lyfius Pharma, manufactures these products, positioning it as a direct beneficiary of these import restrictions. The company confirmed that all relevant information is already in the public domain and no undisclosed material events exist.
Key Highlights
Government of India notified Minimum Import Price (MIP) on Penicillin-G and derivatives on January 29, 2026.
Wholly-owned subsidiary Lyfius Pharma Private Limited manufactures the affected products including 6-APA and Amoxicillin Trihydrate.
Company confirms no undisclosed material information or pending announcements as of January 31, 2026.
The volume spurt is attributed to market reaction to DGFT's official notification regarding domestic consumption protection.
👀 What to Watch
Investors should monitor the margin expansion potential for Lyfius Pharma as the MIP protects domestic production from cheap imports. The stock may see continued interest as the market factors in the competitive advantage for Aurobindo's antibiotic intermediate business.
Aurobindo Pharma Incorporates New Philippines Subsidiary with $2M Initial Capital
Aurobindo Pharma, through its Dutch subsidiary Helix Healthcare B.V., has incorporated a new wholly owned step-down subsidiary in the Philippines named Aurobindo Pharma Philippines Inc. The new entity was established on January 23, 2026, with an initial capital subscription of approximately USD 2 million (120 million PESO). This strategic move is aimed at expanding the company's pharmaceutical product business within the Philippines market. While the initial investment is relatively small for a company of Aurobindo's scale, it marks a clear intent to strengthen its Southeast Asian footprint.
Key Highlights
Incorporated Aurobindo Pharma Philippines Inc. as a 100% step-down subsidiary on January 23, 2026.
Initial investment of approximately USD 2,000,000 (120,000,000 PESO) for 1,200,000 shares.
The primary objective is to expand the pharmaceutical products business in the Philippines.
The transaction was completed via 100% cash subscription to the share capital.
No governmental or regulatory approvals were required for this incorporation.
👀 What to Watch
Investors should view this as a positive step toward geographic diversification in the Southeast Asian market. No immediate action is required as the financial impact is currently minimal, but long-term execution in this region should be monitored.
Aurobindo Pharma Subsidiary Receives Health Canada Approval for Dyrupeg Biosimilar
Aurobindo Pharma's wholly owned subsidiary, CuraTeQ Biologics, has received a Notice of Compliance (NOC) from Health Canada for Dyrupeg, a pegylated filgrastim biosimilar. This regulatory milestone follows previous marketing authorizations for the same product in the European Union and the UK during 2025. The approval confirms that Dyrupeg meets stringent safety, efficacy, and quality standards, showing no clinically meaningful differences from the reference biologic. Furthermore, the company has three additional biosimilar applications currently under review by Health Canada, signaling a robust pipeline expansion in the North American market.
Key Highlights
CuraTeQ Biologics received Health Canada NOC for Dyrupeg (pegylated filgrastim biosimilar).
Dyrupeg previously received marketing authorization in the EU and UK in 2025.
Health Canada verified high similarity to the reference biologic with no safety or quality differences.
Three other biosimilar applications from CuraTeQ are currently under review with Health Canada.
👀 What to Watch
Investors should monitor the commercial launch of Dyrupeg in Canada and the progress of the three pending biosimilar applications which could drive long-term growth in the biologics segment.
Aurobindo Pharma Acquires Khandelwal Labs' Non-Oncology Business for INR 325 Crore
Aurobindo Pharma's subsidiary has acquired the branded non-oncology formulations business of Khandelwal Laboratories for a cash consideration of INR 325 crore. The acquired business reported a turnover of INR 113.5 crore and an EBITDA of INR 29 crore for FY25, implying a valuation of approximately 11.2x EBITDA. The deal includes 23 brands and 67 SKUs, primarily focused on the anti-infective and pain management segments. This acquisition significantly strengthens Aurobindo's domestic presence by adding 470 field staff and over 1,600 stockists.
Key Highlights
Acquisition of 23 brands and 67 SKUs for a total cash consideration of INR 325 crore
Target business generated INR 113.5 crore revenue and INR 29 crore EBITDA in FY25
Transaction adds a 470-member field force and a network of 1,600+ stockists
Strategic focus on high-demand therapeutic areas: anti-infectives and pain management
Acquisition completed on a slump sale basis effective January 1, 2026
👀 What to Watch
This acquisition is a positive move to scale Aurobindo's domestic branded formulations business at a reasonable valuation. Investors should monitor the integration of the new field force and the potential for margin expansion through portfolio synergies.
Aurobindo Pharma Subsidiary Terminates Biosimilar Agreement with BioFactura
CuraTeQ Biologics, a wholly-owned subsidiary of Aurobindo Pharma, has mutually agreed to terminate its license agreement with BioFactura Inc, USA. The agreement, originally signed on July 7, 2023, was for the development and commercialization of BFI-751, a biosimilar to the drug Stelara (Ustekinumab). The company stated that this decision is part of a strategic portfolio prioritization and is not expected to have a material impact on its overall biosimilars strategy. This move allows the company to reallocate resources toward other high-priority projects within its biologics pipeline.
Key Highlights
Termination of the July 7, 2023, agreement with BioFactura Inc for the BFI-751 biosimilar.
BFI-751 is a proposed biosimilar to Stelara (Ustekinumab), which is used for treating autoimmune diseases.
CuraTeQ Biologics previously held global manufacturing rights and a profit-sharing arrangement under the deal.
Management confirms the termination will not have a material impact on the company's long-term biosimilars roadmap.
👀 What to Watch
Investors should view this as a strategic portfolio adjustment rather than a setback, though it is important to monitor the progress of Aurobindo's remaining biosimilar pipeline for future growth drivers.
Aurobindo Pharma to Acquire Additional 20% Stake in Chinese JV for USD 5.125 Million
Aurobindo Pharma's subsidiary, Helix Healthcare B.V., has entered into an agreement to increase its stake in the Chinese joint venture Luoxin Aurovitas from 30% to 50%. The acquisition of the additional 20% stake will cost USD 5.125 million and is expected to close within three months. Additionally, the company has secured a right to acquire the remaining 50% stake by December 2029 for USD 18.86 million. This strategic move is aimed at scaling up the manufacturing of inhalation products in China by adding two high-speed production lines.
Key Highlights
Acquiring 20% additional stake in Luoxin Aurovitas Pharma for a cash consideration of USD 5.125 million.
Secured the right to acquire the balance 50% stake by December 2029 at an agreed price of USD 18.86 million.
Target entity turnover grew significantly from USD 0.16 million in FY23 to USD 2.34 million in FY25.
Investment will fund the addition of 2 high-speed lines to achieve economies of scale in inhalation products.
Target entity has a net worth of USD 15.29 million as of September 30, 2025.
👀 What to Watch
Investors should monitor the ramp-up of the Chinese inhalation business as this acquisition signals a long-term commitment to the region. The fixed-price option for the remaining stake provides a clear roadmap for full ownership by 2029.
Aurobindo Pharma Subsidiary Unit-IV Receives 5 Procedural Observations from US FDA
Aurobindo Pharma's wholly owned subsidiary, APL Healthcare Limited, underwent a US FDA inspection at its Unit-IV facility in Andhra Pradesh from December 8 to December 17, 2025. The inspection concluded with the issuance of a Form 483 containing 5 observations, which the company describes as procedural. Aurobindo Pharma intends to submit a response within the stipulated timelines and maintains that there is no current impact on operations or financials. Investors should track the final classification of these observations to ensure they do not escalate to an Official Action Indicated (OAI) status.
Key Highlights
US FDA inspection of Unit-IV facility completed on December 17, 2025.
Form 483 issued with 5 observations following the 10-day inspection period.
Management stated the observations are procedural and will be addressed promptly.
No immediate quantifiable impact on the financial or operational activities of the unit.
👀 What to Watch
Monitor for the US FDA's final Establishment Inspection Report (EIR) to confirm the severity of the observations. While procedural issues are usually resolvable, any delay in clearance could affect new drug launches from this facility.
AUROPHARMA: US FDA inspects Apitoria Unit-V, issues Form 483 with 3 observations
Aurobindo Pharma's wholly owned subsidiary, Apitoria Pharma Private Limited, had its Unit-V inspected by the US FDA from December 1 to December 12, 2025. Following the inspection, a Form 483 was issued with 3 observations, which Aurobindo Pharma considers procedural in nature. The company plans to respond to the US FDA within the stipulated timelines. Aurobindo Pharma maintains that this development doesn’t have any impact on operations of the facility.
Key Highlights
US FDA inspected Apitoria Pharma's Unit-V from December 01 to December 12, 2025
A Form 483 was issued with 3 observations
The observations are considered procedural in nature
👀 What to Watch
Investors should monitor Aurobindo Pharma's response to the US FDA's observations and any subsequent updates from the company. The impact on future US FDA inspections and product approvals should be closely watched.
